DENVER--(BUSINESS WIRE)--May 3, 2006--Myogen, Inc. (Nasdaq: MYOG - News) today announced results for the integrated analysis of ARIES-1 and ARIES-2, the pivotal Phase 3 trials evaluating ambrisentan, an oral endothelin receptor antagonist (ERA), in pulmonary arterial hypertension (PAH). The integrated analysis was prospectively defined as a supportive analysis of the ARIES trials’ results and was detailed in a data analysis plan submitted to the U.S. Food and Drug Administration prior to unblinding the data for either ARIES trial.
